Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck

Head Neck
April 2012
https://pubmed.ncbi.nlm.nih.gov/21584896/

Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system

Neuro Endocrinol Let
August 2002
https://pubmed.ncbi.nlm.nih.gov/12195238/

Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report

J Pain Symptom Manage
January 2005
https://www.sciencedirect.com/science/article/pii/S0885392404003914

Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer

Exp Biol Med
May 2013
https://pubmed.ncbi.nlm.nih.gov/23856908/

Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway

Int Immunopharmacol
June 2020
https://pubmed.ncbi.nlm.nih.gov/32171145/?from_single_result=32171145&expanded_search_query=32171145

Bernard Bihari, MD: Low-Dose Naltrexone for normalizing immune system function

Altern Ther Health Med
05 November 2013
http://todayspractitioner.com/wp-content/uploads/2013/10/Bernard-Bihari-MD-Low-dose-Naltrexone-for-Normalizing-Immune-System-Function-athm_19_2_bihari_56_65.pdf

Low-dose Naltrexone Targets the Opioid Growth Factor-Opioid Growth Factor Receptor Pathway to Inhibit Cell Proliferation: Mechanistic Evidence From a Tissue

Exp Biol Med (Maywood)
September 2011
https://pubmed.ncbi.nlm.nih.gov/21807817/

The Uses of Low-Dose Naltrexone in Clinical Practice

BMJ Case Reports
January 2018
https://www.researchgate.net/publication/328997819_Issue_4_The_Uses_of_Low-Dose_Naltrexone_in_Clinical_Practice

Off-label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain

Pain Med
May 2014
https://europepmc.org/article/med/24967470

Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis

BMC Medicine
15 January  2019
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1242-0